Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Prepaid Assets (2019 - 2025)

Vivos Therapeutics has reported Prepaid Assets over the past 7 years, most recently at $774000.0 for Q4 2025.

  • Quarterly Prepaid Assets fell 1.15% to $774000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $774000.0 through Dec 2025, down 1.15% year-over-year, with the annual reading at $774000.0 for FY2025, 1.15% down from the prior year.
  • Prepaid Assets was $774000.0 for Q4 2025 at Vivos Therapeutics, up from $565000.0 in the prior quarter.
  • Over five years, Prepaid Assets peaked at $2.3 million in Q1 2022 and troughed at $475000.0 in Q1 2024.
  • The 5-year median for Prepaid Assets is $855313.5 (2021), against an average of $1.1 million.
  • Year-over-year, Prepaid Assets skyrocketed 143.09% in 2022 and then plummeted 64.71% in 2024.
  • A 5-year view of Prepaid Assets shows it stood at $1.6 million in 2021, then fell by 8.06% to $1.4 million in 2022, then tumbled by 57.46% to $616000.0 in 2023, then increased by 27.11% to $783000.0 in 2024, then decreased by 1.15% to $774000.0 in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Prepaid Assets are $774000.0 (Q4 2025), $565000.0 (Q3 2025), and $695000.0 (Q2 2025).